Cargando…
Treatment response to Janus kinase inhibitor in a child affected by Aicardi‐Goutières syndrome
KEY CLINICAL MESSAGE: Baricitinib, a Janus kinase inhibitor (JAK‐inhibitor), seems to contribute to an improvement of a child affected by Aicardi‐Goutières syndrome (AGS), reducing the interferon score and determining a recovery of cognitive, communicative, and relational dysfunctions, while the gro...
Autores principales: | Galli, Jessica, Cattalini, Marco, Loi, Erika, Ferraro, Rosalba Monica, Giliani, Silvia, Orcesi, Simona, Pinelli, Lorenzo, Badolato, Raffaele, Fazzi, Elisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390657/ https://www.ncbi.nlm.nih.gov/pubmed/37534202 http://dx.doi.org/10.1002/ccr3.7724 |
Ejemplares similares
-
Case Report: The JAK-Inhibitor Ruxolitinib Use in Aicardi-Goutieres Syndrome Due to ADAR1 Mutation
por: Cattalini, Marco, et al.
Publicado: (2021) -
IFN-α levels in ruxolitinib-treatead Aicardi-Goutières patient during SARS-CoV-2 infection: A case report
por: Badolato, Raffaele, et al.
Publicado: (2021) -
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis
por: Galli, Jessica, et al.
Publicado: (2018) -
Family History of Autoimmune Disease in Patients with Aicardi-Goutières Syndrome
por: Schmidt, Johanna L., et al.
Publicado: (2012) -
DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes
por: Giordano, Anna Maria Sole, et al.
Publicado: (2022)